Navigation Links
American Pacific Board Continues Focus On Corporate Governance With Appointment Of Independent Lead Director
Date:7/16/2013

LAS VEGAS, July 16 , 2013 /PRNewswire/ -- American Pacific Corporation (Nasdaq: APFC), also known as AMPAC, today announced that its board of directors has established the new position of independent Lead Director and, at its July 8, 2013 meeting, elected Mr. Jan Loeb to the position of Lead Director.

The Lead Director position is intended to enhance the board's focus on corporate governance matters.  In this newly-created role, Mr. Loeb will preside at executive sessions of the board and be responsible for discussing the results of the executive sessions with the Chief Executive Officer. He also will assist in various administrative aspects of communicating with independent directors.

Mr. Loeb, who has been a member of the AMPAC board of directors since 1997, said "I look forward to working with my fellow directors to enhance AMPAC's corporate governance practices and continuing our focus on the voice of the shareholders."

"Over the course of the past few years, we have steadily improved our disclosure and communications with shareholders, as a means of strengthening our overall corporate governance efforts," said Joe Carleone, Chairman and CEO of AMPAC. "Today's announcement continues that trend with the appointment of a Lead Director. I am grateful for Mr. Loeb's willingness to assume this new position as we strive for excellence in AMPAC's corporate governance practices."

RISK FACTORS/FORWARD-LOOKING STATEMENTS

Statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include statements regarding AMPAC's expectations, beliefs or intentions regarding the future and other statements of director's or management's opinions. Forward-looking statements in this press release include, without limitation, statements concerning AMPAC's ability to enhance, strengthen or strive for excellence with respect to its corporate governance practices as well as statements regarding its continuing focus on the voice of the shareholders. Words such as "anticipate", "expect", "can", "will" and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause AMPAC's actual results, market performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by AMPAC that any of its expectations will be achieved. Factors that could cause actual results to differ materially from such forward-looking statements include risks and uncertainties detailed in AMPAC's periodic and other filings with the Securities and Exchange Commission, including in Management's Discussion and Analysis of Financial Condition and Results of Operations and in Risk Factors in AMPAC's annual report on Form 10-K for the fiscal year ended September 30, 2012 and quarterly reports on Form 10-Q for the quarters ended December 31, 2012 and March 31, 2013. All forward-looking statements contained in this release are made as of the date hereof, based on information available to AMPAC as of the date hereof, and AMPAC assumes no obligation to update any forward-looking statement, whether for actual results or otherwise, except as required by law.

ABOUT AMERICAN PACIFIC CORPORATION

American Pacific Corporation (AMPAC) is a leading custom manufacturer of fine chemicals and specialty chemicals within its focused markets.  We supply active pharmaceutical ingredients and advanced intermediates to the pharmaceutical industry.  For the aerospace and defense industry we provide specialty chemicals used in solid rocket motors for space launch and military missiles.  We produce clean agent chemicals for the fire protection industry, as well as electro-chemical equipment for the water treatment industry.  Our products are designed to meet customer specifications and often must meet certain governmental and regulatory approvals. Additional information about us can be obtained by visiting our web site at www.apfc.com.

Contact:  Joseph Carleone – (702) 735-2200
E-mail:  InvestorRelations@apfc.com
Website:  www.apfc.com
 


'/>"/>
SOURCE American Pacific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. American Academy of Family Physicians Foundation Launches Cities for Life
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
4. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
5. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
6. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
7. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
10. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
11. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
Breaking Medicine News(10 mins):